Send to

Choose Destination
Best Pract Res Clin Haematol. 2014 Jun;27(2):107-19. doi: 10.1016/j.beha.2014.07.006. Epub 2014 Jul 18.

Assessing disease burden in patients with classic MPNs.

Author information

Division of Hospital Internal Medicine, Mayo Clinic, AZ, USA. Electronic address:
Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. Electronic address:


Myeloproliferative neoplasm (MPN) disorders including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), are recognized amongst the world of malignancies for their unique disease-burden profiles. Symptom management remains a prime directive for all MPN disorders. Limited by the dramatic heterogeneity and disparate severity amongst symptoms, only recently have researchers possessed the scoring tools necessary to quantify the MPN symptom burden and investigate its role in patient prognosis. In addition to symptom management, clinicians are also tasked with managing the numerous complications that arise from MPN progression including splenomegaly, cytopenias, thrombotic and hemorrhagic events and transformation to MF (from PV or ET) or acute myelogenous leukemia. In this article, we discuss the pleiotropic solidarity of the MPN symptom profile, inherent complications that define the disorders, available patient-reported outcome tools, the role of risk-scoring algorithms and open arenas for ongoing MPN symptom research.


MPN-SAF; essential thrombocythemia; myelofibrosis; myeloproliferative neoplasm; polycythemia vera; risk; symptom

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center